Systemic autoimmune rheumatic diseases (SARDs) are frequently chronic, multisystem, and profoundly debilitating, with patients experiencing symptoms that may parallel the severity experienced by patients with advanced malignancy. Although there have been tremendous advances in the care of patients with SARDs in the last several decades, there remain patients for whom these therapies do not provide meaningful benefit in terms of quantity or quality of life.1,2
Amlani et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: